Mark Cuban Questions PBM ‘Rebate GPO’ Model on LinkedIn

In a recent LinkedIn post, Mark Cuban expressed strong skepticism regarding the new “Rebate GPO” model being introduced by Pharmacy Benefit Managers (PBMs), questioning their role in providing clinical management services. Cuban highlighted the fees associated with these services, which are charged on a per-member-per-month (PMPM) basis to sponsors.

Cuban directly challenged the premise of PBMs offering clinical services, asking:

Can someone explain to me any scenario where a Pharmacy Benefit Manager would be the best source of clinical management services like the following (PMPM)

He then detailed a list of services and their associated PMPM fees, which he appears to view with suspicion. These services include Specialty Drug Management, Digital Health/Remote Care Programs, Care Navigation Services, Medication Adherence Programs, Clinical Analytics & Employer Reporting, Prior Authorization Administration, Biosimilar Conversion Programs, and Outcomes/Value-Based Contract Administration.

Cuban’s Critique of PBM Revenue Control

The core of Mark Cuban’s argument, as presented in his post, centers on the idea that PBMs are leveraging these new fee structures to exert greater control over healthcare decisions, which in turn dictates revenue streams. He posits that the “new PBM scam is to control care decisions.”

Cuban further elaborated on this point, stating:

whoever controls care decisions controls revenue.

This statement suggests a belief that the clinical services offered by PBMs under the “Rebate GPO” are not primarily aimed at improving patient outcomes or reducing costs for employers, but rather at consolidating power and financial gain within the PBM structure.

Analyzing the PBM Fee Structure

The specific fees outlined by Cuban offer a glimpse into the financial arrangements he finds concerning. For instance, Specialty Drug Management is listed with fees ranging from $10 to $100 PMPM, while Digital Health/Remote Care Programs are between $20 and $40 PMPM. Even seemingly straightforward services like Prior Authorization Administration are associated with fees of $1 to $5 PMPM.

As Mark Cuban points out, the breadth of these services, from managing complex specialty medications to offering digital health platforms and ensuring medication adherence, raises questions about whether PBMs are the most effective or cost-efficient providers for such care coordination. In Cuban’s view, the PBM’s involvement in these clinical aspects could be seen as an expansion of their influence beyond their traditional role in managing prescription drug benefits.

Implications for Healthcare Consumers and Employers

Cuban’s critique implies that employers and patients may be paying additional fees for services that could potentially be delivered more effectively or affordably by other entities, or perhaps are being bundled in a way that obscures true costs and benefits. The emphasis on “controlling care decisions” suggests a potential conflict of interest, where the PBM’s financial incentives might not align with the best interests of the patient or the employer sponsoring the health plan.

According to Mark Cuban, the structure of these “Rebate GPOs” warrants close examination by all stakeholders in the healthcare system. His post serves as a call for greater transparency and a deeper understanding of how PBMs are structuring their services and fees, particularly in relation to clinical management and decision-making.

Ultimately, Mark Cuban’s commentary on LinkedIn underscores a broader ongoing debate about the role and influence of PBMs in the American healthcare landscape, urging a critical look at how they manage costs, influence care, and generate revenue.